Sign inJoin waitlistJoin the waitlist

John Livingston

AYA Program Co-Director · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2013–2016
Internal Medicine-Pediatrics
Duke University Hospital
2009–2013
University of Texas Medical Branch at Galveston School of Medicine
2005–2009

Research

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy · 2021 · 2,291 citations
Osteosarcoma
Review · Nature Reviews Disease Primers · 2022 · 559 citations
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2018 · 257 citations

Michael Roth
40 papers
Anthony Conley
31 papers
Shreyaskumar Patel
30 papers
Alexander Lazar
29 papers · 16 as a fellow
Christina Roland
23 papers
Wei-Lien Wang
23 papers
Dejka Araujo
22 papers
Neeta Somaiah
21 papers
Vinod Ravi
20 papers · 2 as a resident
Andrew Bishop
19 papers
Ravin Ratan
19 papers
RB
Robert Benjamin
19 papers

Clinical trials

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2031
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2024–2028
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2023–2027
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2027